These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma]. Huang HQ, Bu Q, Xia ZJ, Lin XB, Wang FH, Li YH, Peng YL, Pan ZH, Wang SS, Lin TY, Jiang WQ, Guan ZZ. Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686 [Abstract] [Full Text] [Related]
4. Humanized anti-CD20 monoclonal antibody (Rituximab) in post transplant B-lymphoproliferative disorder: a retrospective analysis on 32 patients. Milpied N, Vasseur B, Parquet N, Garnier JL, Antoine C, Quartier P, Carret AS, Bouscary D, Faye A, Bourbigot B, Reguerre Y, Stoppa AM, Bourquard P, Hurault de Ligny B, Dubief F, Mathieu-Boue A, Leblond V. Ann Oncol; 2000 Apr; 11 Suppl 1():113-6. PubMed ID: 10707791 [Abstract] [Full Text] [Related]
5. A pilot study of chemoimmunotherapy (cyclophosphamide, prednisone, and rituximab) in patients with post-transplant lymphoproliferative disorder following solid organ transplantation. Orjuela M, Gross TG, Cheung YK, Alobeid B, Morris E, Cairo MS. Clin Cancer Res; 2003 Sep 01; 9(10 Pt 2):3945S-52S. PubMed ID: 14506193 [Abstract] [Full Text] [Related]
6. A pilot study of epratuzumab and rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy in patients with previously untreated, diffuse large B-cell lymphoma. Micallef IN, Kahl BS, Maurer MJ, Dogan A, Ansell SM, Colgan JP, Geyer S, Inwards DJ, White WL, Habermann TM. Cancer; 2006 Dec 15; 107(12):2826-32. PubMed ID: 17099879 [Abstract] [Full Text] [Related]
12. Epstein-Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Oertel S, Trappe RU, Zeidler K, Babel N, Reinke P, Hummel M, Jonas S, Papp-Vary M, Subklewe M, Dörken B, Riess H, Gärtner B. Ann Hematol; 2006 Jul 20; 85(7):478-84. PubMed ID: 16586109 [Abstract] [Full Text] [Related]
13. Prospective phase II trial of extended treatment with rituximab in patients with B-cell post-transplant lymphoproliferative disease. González-Barca E, Domingo-Domenech E, Capote FJ, Gómez-Codina J, Salar A, Bailen A, Ribera JM, López A, Briones J, Muñoz A, Encuentra M, de Sevilla AF, GEL/TAMO (Grupo Español de Linfomas), GELCAB (Grupo para el Estudio de los Linfomas Catalano-Balear), GOTEL (Grupo Oncológico para el Tratamiento y Estudio de los Linfomas). Haematologica; 2007 Nov 20; 92(11):1489-94. PubMed ID: 18024397 [Abstract] [Full Text] [Related]
14. T-cell lymphoid aggregates in bone marrow after rituximab therapy for B-cell follicular lymphoma: a marker of therapeutic efficacy? Raynaud P, Caulet-Maugendre S, Foussard C, Salles G, Moreau A, Rossi JF, Patey M, Rousselet MC, Bene MC, Damotte D, Cornillet Lefebvre P, Martin A, Costes V, GOELAMS group. Hum Pathol; 2008 Feb 20; 39(2):194-200. PubMed ID: 17949786 [Abstract] [Full Text] [Related]